Encephalopathy cost-effectiveness of therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]
Overview
Encephalopathy in its very early stages is cost effective. Early intervention relieves forthcoming complications and the costs that would have come along with them.
Financial Costs
- Cost effectiveness of various therapies depends on the condition.
- Hypothermia for neonatal encephalopathy – The incremental cost per disability-free life year gained was $28,124 (£19,931 ; €26,920) as per the data of 2006 Organisation for Economic Co-operation and Development (OECD). [1]
- Detection of minimal hepatic encephalopathy, especially using the inhibitory control test, and subsequent treatment with lactulose could substantially reduce societal costs by preventing motor vehicle accident. Net program savings over 5 years ranged from $1.7 to 3.6 million.[2]
References
- ↑ Regier DA, Petrou S, Henderson J; et al. (2010). “Cost-effectiveness of therapeutic hypothermia to treat neonatal encephalopathy”. Value Health. 13 (6): 695–702. doi:10.1111/j.1524-4733.2010.00731.x. PMID 20561343.
- ↑ Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM (2012). “Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis”. Hepatology. 55 (4): 1164–71. doi:10.1002/hep.25507. PMID 22135042. Unknown parameter
|month=ignored (help)
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH